EP Patent

EP4045049A1 — Combination therapy for treating a hematological malignancy

Assigned to AstraZeneca AB · Expires 2022-08-24 · 4y expired

What this patent protects

Disclosed are methods of treating cancer comprising administering to a subject in need thereof an effective amount of (3R)‑4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3‑b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one or a pharmaceutically acceptable salt the…

USPTO Abstract

Disclosed are methods of treating cancer comprising administering to a subject in need thereof an effective amount of (3R)‑4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3‑b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one or a pharmaceutically acceptable salt thereof and an effective amount of venetoclax or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP4045049A1
Jurisdiction
EP
Classification
—
Expires
2022-08-24
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.